MATAO

Section NCT
Category Gynecological tumors / Breast cancer
Subcategory Ovarian cancer
Trial Type First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgeryand chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).
Description for laymen The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgeryand chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).
JSON Data { "short_title": "MATAO", "data_mode": "900", "data_mode_number": "000002359", "official_title": "MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "adjuvant", "therapielinie_value": "first", "ctgov_number": "NCT04111978", "eudract_number": null, "general_contact_email": "studiensekretariat.gyn@ukdd.de", "general_contact_phone": "+49 351-4584202", "hauptpruefer_dd_name": "Prof. Dr. med. Pauline Wimberger", "description_laie_de": "Ziel der MATAO (LOGOS) Studie ist die Untersuchung einer spezifischen Behandlung von Eierstockkrebs, welcher explizit \u00d6strogen-Rezeptoren auf der Tumoroberfl\u00e4che tr\u00e4gt. Es wird untersucht, ob Letrozol, ein Medikament, welches routinem\u00e4\u00dfig in der Behandlung von Brustkrebs eingesetzt wird, auch bei dieser Art von Eierstockkrebs einen R\u00fcckfall verhindern kann.", "description_laie_en": "The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgeryand chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).", "description_expert_de": "Ziel der MATAO (LOGOS) Studie ist die Untersuchung einer spezifischen Behandlung von Eierstockkrebs, welcher explizit \u00d6strogen-Rezeptoren auf der Tumoroberfl\u00e4che tr\u00e4gt. Es wird untersucht, ob Letrozol, ein Medikament, welches routinem\u00e4\u00dfig in der Behandlung von Brustkrebs eingesetzt wird, auch bei dieser Art von Eierstockkrebs einen R\u00fcckfall verhindern kann.", "description_expert_en": "The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgeryand chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).", "rechtsgrundlage_value": "AMG", "phase_amg_value": "III", "main_cat_id": 3, "sub_cat_id": 15 }
Settings
Short name 900-000002359